Postmarketing Surveillance of Pregnancy Outcomes With Dolutegravir Use

J Acquir Immune Defic Syndr. 2020 Jan 1;83(1):e2-e5. doi: 10.1097/QAI.0000000000002213.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Combinations
  • Female
  • HIV Infections / drug therapy*
  • HIV Integrase Inhibitors / administration & dosage
  • HIV Integrase Inhibitors / therapeutic use*
  • Heterocyclic Compounds, 3-Ring / administration & dosage
  • Heterocyclic Compounds, 3-Ring / therapeutic use*
  • Humans
  • Oxazines
  • Piperazines
  • Pregnancy
  • Pregnancy Complications, Infectious / drug therapy*
  • Product Surveillance, Postmarketing*
  • Pyridones

Substances

  • Drug Combinations
  • HIV Integrase Inhibitors
  • Heterocyclic Compounds, 3-Ring
  • Oxazines
  • Piperazines
  • Pyridones
  • dolutegravir